Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Emory University
With
Cephalon
Approximately 100 male and female outpatients, who are between the ages of 18 and 65, will be enrolled at four sites in the United States. This study consists of two parts. The first part consists of 6 weeks of open label treatment with a selected SSRI \& double blind treatment with Provigil or placebo (inactive medication).
After the six week double blind treatment phase all patients will enter a four week open label treatment phase with Provigil. The dose of Provigil is not to exceed 400 mg and cannot be less than 100 mg per day. They will continue taking the prescribed SSRI.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Major Depressive Disorder
MADRS score ≥ 15 at both screen \& baseline.
Significant fatigue as evidenced by FSS ≥4 at both screen \& baseline.
Excessive sleepiness as evidenced by ESS ≥ 10 at both screen \& baseline.
You may not be if
Treatment refractory depression
Serious or unstable medical condition.
Pregnancy
Primary diagnosis of another Axis I or II disorder
Alcohol or substance abuse or dependence within the past 12 months.